Y-Intercept (HK)’s Syndax Pharmaceuticals SNDX Stock Holding History

Y-Intercept (HK)’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$312K	Sell	16,621 -196,092	-92%	-$3.96M	0.01%	1391
2026 Q2	$4.65M	Buy	+212,713	New	+$4.42M	0.09%	304
2026 Q1	–	Sell	-155,916	Closed	-$3.28M	–	2018
2025 Q4	$3.28M	Buy	155,916 +55,065	+55%	+$961K	0.07%	387
2025 Q3	$1.55M	Sell	100,851 -176,081	-64%	-$2.3M	0.04%	759
2025 Q2	$2.59M	Buy	+276,932	New	+$3.05M	0.06%	482
2025 Q1	–	Sell	-83,297	Closed	-$1.1M	–	1577
2024 Q4	$1.1M	Buy	83,297 +1,995	+2%	+$34.1K	0.07%	390
2024 Q3	$1.57M	Buy	81,302 +61,916	+319%	+$1.28M	0.1%	278
2024 Q2	$398K	Buy	+19,386	New	+$406K	0.02%	913
2023 Q4	–	Sell	-22,043	Closed	-$320K	–	1612
2023 Q3	$320K	Buy	+22,043	New	+$417K	0.03%	738

Other funds holding SNDX

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Post Resch Tallon Group Pittsford, New York $146M AUM 18.19% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

CIA

Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Y-Intercept (HK)'s SNDX Position: Q3 2026 in Review

Y-Intercept (HK) reduced its Syndax Pharmaceuticals (SNDX) stake by 92% in Q3 2026, selling an estimated $3.96M and leaving 16,621 shares worth $312K. The position accounts for 0.01% of the portfolio, ranked #1391.

Y-Intercept (HK) first reported a position in SNDX in Q3 2023 and has held it in 9 quarters since. The position peaked at $4.65M in Q2 2026. 21 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

Y-Intercept (HK) held 16,621 shares of Syndax Pharmaceuticals worth $312K as of Q3 2026.
Y-Intercept (HK) sold 196,092 Syndax Pharmaceuticals shares in Q3 2026, an estimated $3.96M.
Syndax Pharmaceuticals made up 0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1391 holding.
Y-Intercept (HK) first reported a position in Syndax Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
Y-Intercept (HK)'s Syndax Pharmaceuticals position peaked at $4.65M in Q2 2026.
21 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.